CN104771473B - A kind of Chinese medicine composition - Google Patents
A kind of Chinese medicine composition Download PDFInfo
- Publication number
- CN104771473B CN104771473B CN201510149326.5A CN201510149326A CN104771473B CN 104771473 B CN104771473 B CN 104771473B CN 201510149326 A CN201510149326 A CN 201510149326A CN 104771473 B CN104771473 B CN 104771473B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- chinese medicine
- medicine composition
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 82
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 239000000843 powder Substances 0.000 claims abstract description 54
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 241000218691 Cupressaceae Species 0.000 claims abstract description 17
- 210000000582 semen Anatomy 0.000 claims abstract description 17
- 241000756943 Codonopsis Species 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 13
- 230000004515 progressive myopia Effects 0.000 claims description 11
- 208000003464 asthenopia Diseases 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 2
- 210000005252 bulbus oculi Anatomy 0.000 abstract description 8
- 230000004438 eyesight Effects 0.000 abstract description 8
- 210000001519 tissue Anatomy 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 7
- 230000004423 myopia development Effects 0.000 abstract description 6
- 239000000790 retinal pigment Substances 0.000 abstract description 5
- 230000002159 abnormal effect Effects 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 210000004694 pigment cell Anatomy 0.000 abstract description 4
- 210000003786 sclera Anatomy 0.000 abstract description 4
- 239000007787 solid Substances 0.000 abstract description 3
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 210000005036 nerve Anatomy 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract 1
- 208000001491 myopia Diseases 0.000 description 38
- 230000004379 myopia Effects 0.000 description 31
- 210000001508 eye Anatomy 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000008859 change Effects 0.000 description 9
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 8
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 8
- 210000001525 retina Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 210000002159 anterior chamber Anatomy 0.000 description 3
- 230000004323 axial length Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000979 retarding effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 235000003805 Musa ABB Group Nutrition 0.000 description 2
- 240000008790 Musa x paradisiaca Species 0.000 description 2
- 235000015266 Plantago major Nutrition 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000004340 degenerative myopia Effects 0.000 description 2
- 208000001309 degenerative myopia Diseases 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 230000004341 simple myopia Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010059397 Antimetropia Diseases 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241001113925 Buddleja Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 240000008365 Celosia argentea Species 0.000 description 1
- 235000000722 Celosia argentea Nutrition 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 241001511570 Myopias Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000003857 Parmelia saxatilis Species 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 239000000864 hyperglycemic agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition, including the following raw material medicine, 10 30 parts by weight Radix Codonopsis, the 3 10 parts by weight Fructuss Sophorae, 3 15 parts by weight golden cypresses, 5 15 parts by weight semen astragali complanatis and 13 parts by weight pearl powders, preferably also include 13 parts by weight amber powders and 6 15 parts by weight bulbus fritillariae cirrhosaes.Wherein Radix Codonopsis and the invigorating the spleen improving eyesight of semen astragali complanati Yiyang, the function of increasing retinal photoreceptor cells is monarch drug in a prescription, the Fructus Sophorae, golden cypress clears liver and improve vision, bitter cold consolidating the yin, the abnormal heat for removing retinal pigment cell's layer is ministerial drug, pearl powder, which is calmed the nerves, to be consolidated, the toughness for strengthening scleral tissue is adjutant, above-mentioned medicinal material is with " Yiyang consolidating the yin " for rules for the treatment of prescription, flavour of a drug are simple, mild in medicine property and, cooperate, synergy, by adjusting organism balance, remove abnormal heat, solid eyeball tissue, suppress sclera deformation, strengthen the function of retinal pigment cell, so as to prevent, delay and control the development of myopia.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, and in particular to one kind alleviates visual fatigue, delays or control myopia progression, control
The Chinese medicine composition of near-sighted ocular complication is treated, belongs to field of traditional Chinese.
Background technology
Stepped into information network times, physical exertion are increasingly reduced the mankind, mental work load increase, the epoch
Change the life style of people, vision system has to receive more information that (90% external information is connect by eyes
Receive), eyes are the most sensitive organs of body, and the most tired organ of load at present, in order to meet for a long time closely
Read and accurate operation, human eye then need to carry out the regulation of long adaptation near work, caused near-sighted in crowd
Incidence increases significantly, and especially teenager's body and eye development stage excess load has used vision system to cause axis oculi to prolong
Long, myopia occurs.Reach 60-80% in the adolescents in China myopia incidence of disease, and it is annual still in incremental, key school
Rate of myopia is up to 90%.Myopia has become one of major lesions of visual fatigue, according to the degree of complication, is divided into pure
Myopia and pathological myopia, wherein simple myopia diopter is less than -6.00D more, and pathological myopia is then more than -6.00D.
The main harm of myopia is long sight function reduction and serious myopia complication, causes many fields for needing long sight function
Talent shortage, space industry, military field, sports etc., it is very may be used that rear national long sight function collective, which degenerates, for many years
The phenomenon of fearness, the side effect that it brings are that we can not imagine, wherein retinosis caused by complication comes off, macula lutea becomes
An important factor for property bleeding is blinding.WHO in VISION2020 myopia be included in it is urgently to be resolved hurrily can blinding illness in eye it
One.Therefore, juvenile shortsightedness colony is prevented and intervention be one there is an urgent need to study the problem of.
Due to the complexity of the myopia origin cause of formation, the myopia there is presently no the oral drugs specifically for myopia therapeutic
Operation is still the method cured the symptoms, not the disease, and myopia laser surgical technic in the late two decades continues to develop, and is in ocular cornea
On the concavees lens effect artificially made, the development of myopia can not be prevented.As molecular biology and immunology etc. study skill
The progress of art, numerous studies confirm that the development of myopia depends on the near-sighted regulatory mechanism of retina, have been currently known a variety of
Neurotransmitter and bioactive substance take part in the regulation and control of eyeball growth after birth, and research shows that the fuzzy imaging of retina can be broken
The normal transmission mechanism of bad visual signal, cause the change of cell micro-environment and multifunctional cytokine (near-sighted courier), in order to
" compensation " dioptric mistake, retina adjustment signal are ultimately applied to sclera by cascade system, cause a series of Myopias of eyeball
Change.Find that the material that induction myopia occurs is mainly derived from layer of retina,fiber in experimental animal myopia studies, in near-sighted shape
Some chemical substances of view film expression can increase and decrease during, wherein studying more deep has dopamine, acetyl courage
Alkali, hyperglycemic factor, Basic Fibroblast Growth Factor etc., this kind of material exhibits are the inhibitory action to myopic eye growth, and another
A kind of material includes the table in the process of experimental myopia such as MMP-2, retinoic acid-β, vasoactive peptide
It is now obvious up-regulation；Therefore, the near-sighted regulatory mechanism of retina is carried out intervening the method for being only myopia and effecting a permanent cure.
Chinese patent literature CN103768283A once disclosed a kind of Chinese medicine for treating a variety of eye illnesses, and it includes different ratio
Safflower, the fruit of Chinese wolfberry, semen astragali complanati, the fruit of glossy privet, plantain seed, the fruit of Chinese magnoliavine, the seed of feather cockscomb, cassia seed, honeysuckle, Jasmine, feverfew
The taste Chinese medicine of flower, parmelia saxatilis, butterflybush flower etc. 27 is made, in addition, Chinese patent literature CN1168277A also discloses a kind of eyesight punching
Agent, the electuary is by the taste Chinese medicine system of the dried rhizome of rehmannia, cultivated land, the fruit of Chinese wolfberry, chrysanthemum, Poria cocos, plantain seed, the fruit of Chinese magnoliavine, Chang Can, golden cypress etc. 14
Into the Chinese medicine preparation that above-mentioned patent document provides is nourshing blood and promoting blood circulation, nourishing liver and kidney, class of clearing liver and improving vision traditional Chinese medicine ingredients composition, is being distinguished
It can be used for many ophthalmology miscellaneous diseases of external eyes and interior eye on the basis of card, without the special theoretical direction for myopia and grind
Study carefully.
The content of the invention
To solve to lack the Chinese medicine composition of special treatment myopia in the prior art, so provide a kind of compound it is simple,
The definite Chinese medicine composition of drug effect, with " Yiyang consolidating the yin method " for principle of reatment, prevent, delay and control the development of myopia.
Therefore, the technical scheme that the application takes is,
A kind of Chinese medicine composition, including the following raw material medicine, 10-30 parts by weight Radix Codonopsis, the 3-10 parts by weight Fructus Sophorae, 3-15 weight
Part golden cypress, 5-15 parts by weight semen astragali complanati and 1-3 parts by weight pearl powders.
Preferably, described Chinese medicine composition, in addition to 1-3 parts by weight amber powder and 6-15 parts by weight bulbus fritillariae cirrhosaes.
Preferably, in described Chinese medicine composition, Radix Codonopsis 25-30 parts by weight, Fructus Sophorae 5-10 parts by weight, golden cypress 10-15 weights
Measure part, semen astragali complanati 10-15 parts by weight.
Preferably, in described Chinese medicine composition, pearl powder 1.5-3 parts by weight and amber powder 1.5-3 parts by weight.
Preferably, in described Chinese medicine composition, the Chinese medicine composition is made according to common process to be clinically subjected to
Formulation.
Preferably, in described Chinese medicine composition, the formulation include powder, water-bindered pill agent, tablet, capsule, aqua and
Decoction.
Preferably, in the preparation method of the Chinese medicine composition, bulk drug co-grinding is formed into Ultramicro-powder first, then will
The step of Ultramicro-powder is used to prepare tablet, the water-bindered pill or capsule.
Compared with prior art, the invention has the advantages that,
(1) ancient Chinese medicine thinks the genesis mechanism of myopia caused by " the moon is had a surplus, YANG deficiency ".And the applicant passes through
The mechanism that long-term clinical practice thinks to cause myopia to be formed is " the moon is had a surplus, and the deficiency of yang is high ", and " YANG deficiency " is not really " sun
It is empty ", but the Early manifestation of " deficiency of yang ", i.e. " deficiency of yang is high ", it is the false high Sheng that body YANG deficiency occurs with anti-cloudy, " empty
In the presence of sun ", cause eyeball Overgrowth, axis oculi extends, visual function declines, and myopia occurs.Coagulated therefore, applicant summarizes
Practise the rules for the treatment of and method of retarding myopia progression.That is " Yiyang consolidating the yin " rule, QI invigorating life sun is filtered out, the Chinese medicine of bitter cold consolidating the yin is matched somebody with somebody
Side, Radix Codonopsis 10-30 parts by weight, Fructus Sophorae 3-10 parts by weight, golden cypress 3-10 parts by weight, semen astragali complanati 5-10 parts by weight, pearl powder 1-3 weights
Part, wherein Radix Codonopsis and the invigorating the spleen improving eyesight of semen astragali complanati Yiyang are measured, the function of increasing retinal photoreceptor cells is monarch drug in a prescription, and the Fructus Sophorae, golden cypress are clear
Liver improving eyesight, bitter cold consolidating the yin, the abnormal heat for removing retinal pigment cell's layer is ministerial drug, and pearl powder, which is calmed the nerves, to be consolidated, and strengthens scleral tissue
Toughness be adjutant, above-mentioned medicinal material flavour of a drug are simple, mild in medicine property and, cooperate, synergy, by the shape for improving body
State, abnormal heat is removed, solid eyeball tissue, suppresses sclera deformation, strengthens the function of retinal pigment cell, so as to delay or control
The occurrence and development of myopia.
(2) in the alleviation of the application and the Chinese medicine composition of a variety of eye illnesses for the treatment of, in addition to bulbus fritillariae cirrhosae 6-15 parts by weight
The effect of assisting consolidating the yin, the toughness of each layer tissue of the amber powder 1-3 parts by weight solid eyeballs of blood-promoting and mind-easing profit water.
(3) it is on the basis of TCM Ophthalmology Clinical and experimental study originally to declare, and proposes teenager's simple myopia first
For caused by " the moon is had a surplus, the deficiency of yang is high " constitution, and propose the hypothesis in theory of " Yiyang consolidating the yin method " retarding myopia progression.Early stage exists " benefit
Under positive consolidating the yin " theoretical direction, the experiment that Chinese prescription has carried out multiple batches of large sample to guinea pigs with form deprivation myopia is filtered out
Research, experimental result are shown：There were significant differences compared with control group for treatment group's cavy axis oculi, and myopia progression substantially delays, immune detection
Near-sighted Guinea Pig Retina pigment epithelium-choroid MMP-2 (MMP-2) expression is lowered, sclera collagen
Protein structure and Normal group no significant difference.Experimental result supports the traditional Chinese medical science " Yiyang consolidating the yin " rules for the treatment of control myopia progression
Feasibility.On the basis of Chinese medicine preparation study on the efficiency, we are further studied the dose-effect and timeliness of formula, and
Small sample clinical research is carried out.
Brief description of the drawings
In order that present disclosure is more likely to be clearly understood, specific embodiment and combination below according to the present invention
Accompanying drawing, the present invention is further detailed explanation, wherein
Fig. 1 is the protein level that MMP-2 is expressed in eyeball tissue.
Embodiment
Embodiment 1
The raw material medicine composition of the Chinese medicine composition of the present embodiment is as follows, Radix Codonopsis 25g, Fructus Sophorae 10g, golden cypress 8g, semen astragali complanati 6g,
Pearl powder 3g, amber powder 3g and bulbus fritillariae cirrhosae 6g.
The bulk drug of above-mentioned formula is mixed, 80-100 mesh sieve is crossed after crushing and obtains bulk drug fine powder, will be above-mentioned thin
Powder, which is fitted into commercially available capsule shells, forms capsule, wherein containing fine powder 0.5g in every capsule.
Embodiment 2
The raw material medicine composition of the Chinese medicine composition of the present embodiment is as follows, Radix Codonopsis 20g, Fructus Sophorae 10g, golden cypress 10g, semen astragali complanati
10g and pearl powder 1.5g.
Above-mentioned raw materials medicine is mixed, after being crushed to it, it decocted with 20 times of water of medicinal material weight, decoction carries
Taking 2 times, extraction 2 hours, are collected and merge extract solution afterwards every time, and extract solution is condensed into the medicinal extract that relative density is 1.15,
It is diluted with the water of 7 times of medicinal extract volume again, extract solution must be clarified by filtering；Clarification extract solution is passed through absorption, washing, solution
The flow velocity of analysis is the large pore resin absorption column of 10 times of bed volume/hours, is first washed with water, then is washed with 20% ethanol, finally with
50% ethanol parses；By desorbed solution recovery ethanol to without alcohol taste, concentrate, spray drying, obtain extract dry powder, and the medicinal extract is done
Powder is ground into fine powder, then 0.1-1 μm of Ultramicro-powder is made through superfine communication technique, and appropriate amount of starch system is added into above-mentioned Ultramicro-powder
Grain, talcum powder mixing is added, tabletting, packs and produces tablet.
Embodiment 3
The raw material medicine composition of the Chinese medicine composition of the present embodiment is as follows, Radix Codonopsis 25g, Fructus Sophorae 10g, golden cypress 10g, semen astragali complanati
10g, pearl powder 1.5g, amber powder 1.5g and bulbus fritillariae cirrhosae 6g.
The bulk drug of above-mentioned formula is mixed, 1-10 μm of Ultramicro-powder is made after preliminary crushing through superfine communication technique again,
Above-mentioned Ultramicro-powder and physiological saline are mixed to form suspension so that aqua is made, wherein being mixed into ultra micro in physiological saline per 5ml
Powder 1.0g.
Embodiment 4
The raw material medicine composition of the Chinese medicine composition of the present embodiment is as follows, Radix Codonopsis 30g, Fructus Sophorae 8g, golden cypress 10g, semen astragali complanati
10g, pearl powder 1.5g, amber powder 1.0g and bulbus fritillariae cirrhosae 10g.
Above-mentioned raw materials medicine is mixed and is ground into coarse powder, boils 2 times with the appropriate decocting of above-mentioned mixing medicinal material weight, every time
1.5 hours, collecting decoction, filtration, filtrate was concentrated into relative density 1.08 (90-95 °C), room temperature to be cooled to, and added the ethanol of equivalent
Precipitation, supernatant concentration is taken to add 1 times of amount of water to relative density 1.2 (60-65 °C), stirring, stand 8 hours, take supernatant concentration
To the clear cream of relative density 1.38 (60-65 °C).By 1 part of clear cream, 3 parts of sucrose, particle is made in 1.25 parts of dextrin and appropriate amount of ethanol,
It is drying to obtain granule.
Embodiment 5
The raw material medicine composition of the Chinese medicine composition of the present embodiment is as follows, Radix Codonopsis 20g, Fructus Sophorae 5g, golden cypress 3g, semen astragali complanati 10g,
Pearl powder 1.0g, amber powder 1.5g and bulbus fritillariae cirrhosae 6g.
(1) bulk drug of above-mentioned formula is mixed, added water to cook 1 hour, filtered, obtain one-level filter residue and one-level filtrate,
The dosage of this step reclaimed water is 15 times of the medicinal mixture quality；
(2) add water to continue to decoct 1.5 hours into the one-level filter residue, filtering, obtain two level filter residue and two level filtrate, this
The dosage of step reclaimed water is 12 times of the first-level filtering slag amount；
(3) the one-level filtrate and the two level filtrate are mixed, heating is concentrated into relative density as 1.02 (20 DEG C)
Concentrate, adds potassium sorbate and sweetener, wherein potassium sorbate addition account for the concentrate quality 0.06wt%, sweetener
Addition accounts for the concentrate quality 0.06wt%, stirs, and stands 50min, takes supernatant to produce oral liquid.
Embodiment 6
The raw material medicine composition of the Chinese medicine composition of the present embodiment is as follows, Radix Codonopsis 20g, Fructus Sophorae 4g, golden cypress 6g, semen astragali complanati 15g,
Pearl powder 1.0g, amber powder 1.5g and bulbus fritillariae cirrhosae 10g.
Fine powder is ground into after the bulk drug of said ratio is mixed, takes above-mentioned fine powder to add water to cook 3 times, adds 10 for the first time
The water of the fine powder weight again, decoction 2 hours, second of the water for adding 8 times of fine powder weight, decoct 3 hours, third time adds
Enter the water of 9 times of fine powder weight, decoct 1 hour, merge filtering gained decoction liquor, gained filtrate decompression is concentrated at 50 DEG C
Relative density is 1.25 clear cream；The clear cream of acquisition is subjected to vacuum belt type drying, dried cream powder is made, then the mixing of 1g dextrin is equal
Even, molding, shaping simultaneously dry the water-bindered pill that obtained particle diameter is 1mm.
Embodiment 7
The raw material medicine composition of the Chinese medicine composition of the present embodiment is as follows, Radix Codonopsis 25g, Fructus Sophorae 10g, golden cypress 15g, semen astragali complanati
10g and pearl powder 1.5g.
Fine powder is ground into after the bulk drug of said ratio is mixed, 1g dextrin is then added and is well mixed, molding, shaping are simultaneously
Dry the water-bindered pill that obtained particle diameter is 1mm.
Clinically acceptable any formulation, preferably powder can be made in the Chinese medicine composition of the application according to common process,
Water-bindered pill agent, tablet, capsule, aqua or decoction.
Evaluate example
In order to evaluate alleviating visual fatigue, retarding myopia progression, preventing and treating closely for Chinese medicine composition of the present invention
Depending on the effect in complication, its medication effect is evaluated.
1st, zoopery partial data
Experiment uses form-deprivation Infection Model in Guinea Pig, and the suture of cavy right eye carries out form deprivation, using random digit
48 3 week old are spent cavy to be randomly divided into three groups by table method, and A groups give eyelid suture six weeks without any intervention, B, C group right eye, its
Middle B groups are not administered, and C groups give Chinese medicine gavage, daily 5ML, and the Chinese medicine that C groups give Chinese medicine gavage is to prepare to be formed in embodiment 3
Aqua.
(1) change of axis oculi is observed
The super measurement anterior chamber depths of A, crystal thickness, vitreous cavity depth, axiallength are adopted as observation index before and after experiment
Dyed with HE, microphotograph and Volocity softwares measure Posterior pole retina and scleral thickness, Fluorescent immunohistochemistry
It is comprehensive with the expression of the observation of Western blot blottings MMP-2 and COL- I in the tissue as molecular biology observation index
Evaluate under the guidance of " Yiyang consolidating the yin " rules for the treatment of, influence of the Chinese medicine composition of the present invention to guinea pigs with form deprivation development of myopia is bright
True effect of the medicine on living animal, its data are as shown in table 1.
Table 1 A, B, C group animal model experiment result
It can be drawn from the result in above-mentioned table 1, A groups：Before (Normal group, not suturing not medication) animal right and left eyes
Relatively illustrate normally to move without in the case of any intervening measure without significant difference in each index group of room, crystal, vitreum, axis oculi
Thing right and left eyes are not in any statistically to have in terms of anterior chamber, crystal, vitreum, axiallength with the growth at age
The performance of significant difference.B groups (blank control group, the right eye suture induction property deprived myopia occur, and left eye does not suture) animal or so
In each index group of eye relatively, without significant difference, there were significant differences for vitreum depth, axiallength, illustrates right eye for anterior chamber, crystal value
By 6w eyelid suture, there is ultrastructure in form deprivation myopia, own control result has significant difference.(right eye stitches C groups
Close, left eye do not suture, Chinese medicinal aqua gavage group) in animal or so camera oculi anterior, crystal, vitreum, axis oculi group relatively without significance difference
It is different, illustrate in right eye eyelid suture, while after giving Yiyang consolidating the yin Chinese medicinal aqua 6w, Drug inhibition right eye form-deprivation is near
Depending on the formation of eye.
(2) Western blot blottings：Observe the expression for the protein level that MMP-2 is expressed in eyeball tissue.
This method quantitatively detects retinal pigment epithelium-choroid layer MMP-2 expressions from protein expression level, by
Fig. 1 can be seen that its result is visible at molecular weight 72kDa and 66kDa, the strong signal band of B groups form deprivation myopia appearance, C groups (in
Medicine intervention group) for signal band than weak, A groups (Normal group) are most weak.It is indicated above that the application Chinese medicine preparation suppresses myopia
The approach of development can reduce RPE- choroid layer matrix metalloproteinases MMP-2.
2nd, partial clinical data
2.1 case selections, father and mother's high myopia, outer eye Other diseases and general disease are excluded between -2014 years 2013
Situation, screening myopic refractive is in 250-550 degree, and astigmatism is less than 150 degree, and antimetropia is corrected defects of vision 1.0 less than 200 degree
8-13 year children 33 above, wherein voluntary medication group 18, blank control group 15.All case Jun You main suit myopia hairs
Speed is opened up, and symptom can not be persistently waited with children's eyes sense of fatigue, sensation of dryness, sour swollen, photophobia, reading.
The change of myopic refractive degree, non-Corneal Contact measurement vitreous chamber depth and eye are observed in 2.2 observed contents, Mydriasis Test ＆ Optometry
The change of axle.December observing time.
2.3 medications, the capsule being prepared from embodiment 1,1.5 grams every time, 2 times a day.
2.4 clinical efficacies, medication child myopia refractive development speed more than June averagely reduce 75D compared with control group children,
Treatment group's children with myopia axis oculi is average average in 25.35mm, two groups of difference 0.70mm in 24.65mm, control group.Treatment group children
The dry and astringent symptom of eye fatigue is obviously improved, and parent main suit's children's eyes have god, the dry and astringent symptom mitigation of fatigue, grow normal,
Any adverse reaction is not found.
Obviously, above-described embodiment is only intended to clearly illustrate example, and is not the restriction to embodiment.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of change or
Change.There is no necessity and possibility to exhaust all the enbodiments.And the obvious change thus extended out or
Among changing still in the protection domain of the invention.
Claims (6)
1. a kind of Chinese medicine composition that can alleviate visual fatigue, delay or control myopia progression, it is characterised in that by the following raw material
Medicine forms, 10-30 parts by weight Radix Codonopsis, the 3-10 parts by weight Fructus Sophorae, 3-15 parts by weight golden cypress, 5-15 parts by weight semen astragali complanati and 1-3 weights
Measure part pearl powder, 1-3 parts by weight amber powder and 6-15 parts by weight bulbus fritillariae cirrhosaes.
2. the Chinese medicine composition according to claim 1 that visual fatigue can be alleviated, delay or control myopia progression, its feature
It is, Radix Codonopsis 25-30 parts by weight, Fructus Sophorae 5-10 parts by weight, golden cypress 10-15 parts by weight, semen astragali complanati 10-15 parts by weight, pearl powder
1-3 parts by weight, amber powder 1-3 parts by weight and bulbus fritillariae cirrhosae 6-15 parts by weight.
3. the Chinese medicine composition according to claim 2 that visual fatigue can be alleviated, delay or control myopia progression, its feature
It is, Radix Codonopsis 25-30 parts by weight, Fructus Sophorae 5-10 parts by weight, golden cypress 10-15 parts by weight, semen astragali complanati 10-15 parts by weight, pearl powder
1.5-3 parts by weight, amber powder 1.5-3 parts by weight and bulbus fritillariae cirrhosae 6-15 parts by weight.
4. according to any described Chinese medicine compositions that can alleviate visual fatigue, delay or control myopia progression of claim 1-3,
Characterized in that, clinically acceptable formulation is made according to common process in the Chinese medicine composition.
5. the Chinese medicine composition according to claim 4 that visual fatigue can be alleviated, delay or control myopia progression, its feature
It is, the formulation is powder, water-bindered pill agent, tablet, capsule, aqua or decoction.
6. Chinese medicine composition according to claim 4, it is characterised in that first in the preparation method of the Chinese medicine composition
Bulk drug co-grinding is first formed into Ultramicro-powder, then by the Ultramicro-powder for preparing tablet, the water-bindered pill or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510149326.5A CN104771473B (en) | 2015-03-31 | 2015-03-31 | A kind of Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510149326.5A CN104771473B (en) | 2015-03-31 | 2015-03-31 | A kind of Chinese medicine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104771473A CN104771473A (en) | 2015-07-15 |
| CN104771473B true CN104771473B (en) | 2018-01-23 |
Family
ID=53613458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510149326.5A Active CN104771473B (en) | 2015-03-31 | 2015-03-31 | A kind of Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104771473B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106977A (en) * | 2009-12-24 | 2011-06-29 | 孟繁英 | Externally-applied sturdy vision eyeshield liquid medicine for preventing and treating oculopathy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101067339B1 (en) * | 2008-11-28 | 2011-09-26 | 충청남도 연기군(연기군농업기술센터) | Composition for inhibiting MMP-2 production |
-
2015
- 2015-03-31 CN CN201510149326.5A patent/CN104771473B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106977A (en) * | 2009-12-24 | 2011-06-29 | 孟繁英 | Externally-applied sturdy vision eyeshield liquid medicine for preventing and treating oculopathy |
Non-Patent Citations (1)
| Title |
|---|
| 中药干预对剥夺性近视动物眼轴及相关细胞因子的影响;高然等;《世界中医药学会联合会眼科专业委员会第四届学术年会、中国中西医结合学会眼科专业委员会第十二届中西医结合学术年会、中华中医药学会眼科分会第十二届中医眼科学术年会、山东省第十七次眼科学学术会议论文汇编》;20130516;第463-464页，尤其是第463页第1段，第464页第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104771473A (en) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102631558B (en) | Medicament for treating eye disease and preparation method of medicament | |
| CN104225265B (en) | A kind of Traditional Chinese medicine composition for relieving asthenopia | |
| CN103520621B (en) | A kind of Chinese medicine composition for the treatment of senile cataract and preparation method thereof | |
| CN102600386A (en) | Chinese herba preparation for treating eye inflammation and preparation method of Chinese herba preparation | |
| CN103705638B (en) | Chinese medicine composition of a kind of alleviating asthenopia and preparation method thereof | |
| CN101856418A (en) | Pharmaceutical preparation for preventing nephritis and preparation method thereof | |
| CN109512870B (en) | Pharmaceutical composition, preparation method and application thereof | |
| CN104771473B (en) | A kind of Chinese medicine composition | |
| CN104771474B (en) | A kind of Chinese medicine composition alleviate visual fatigue and prevention, delay and treat myopia and its complication in application | |
| CN102846871B (en) | Chinese herbal preparation for treating liver-fire ascending type supraorbital neuralgia and preparation method thereof | |
| CN102258709B (en) | Traditional Chinese medicine preparation for treating diabetic retinopathy, and preparation method thereof | |
| CN109260397A (en) | A kind of Chinese medicine composition for treating Vascular retinopathy | |
| CN104306546B (en) | A kind of Chinese medicine composition and its decoction, pill and powder for being used to treat optic atrophy | |
| CN101199673A (en) | Chinese medicine compound for treating light-headedness, eyes-drying and conjunctivitis and preparing method thereof | |
| CN112294963B (en) | Pharmaceutical composition for treating age-related macular degeneration | |
| CN104740334B (en) | It is a kind of to be used to prevent and treat Chinese medicine composition of cataract and preparation method thereof | |
| CN103251725B (en) | A kind of application of Chinese medicine composition in treatment keratitis medicine is prepared | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN113663026A (en) | Traditional Chinese medicine eye-protecting liquid and preparation method thereof | |
| CN101390997B (en) | Jianmu capsule and preparation method thereof | |
| CN111939209A (en) | Medicine for treating glaucoma and preparation method thereof | |
| CN104689107A (en) | Traditional Chinese medicine for treating nearsightedness and preparation method thereof | |
| CN102973743B (en) | Clear vision capsule | |
| CN103446543A (en) | Traditional Chinese medicine for treating thyroid associated ophthalmopathy in acute stage | |
| CN107753589B (en) | A Chinese medicinal composition for treating diabetes, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210205 Address after: 100730 No. 1 East Lane, Beijing, Dongcheng District Patentee after: BEIJING TONGREN HOSPITAL, CAPITAL MEDICAL University Address before: 100730 No.1 Dongjiaominxiang street, Dongcheng District, Beijing Patentee before: Ma Dongli |